July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities
Abstract
Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome.1–3 A scientific statement from the Heart Failure Association (HFA) described most common HFpEF phenotypes, related comorbidities and treatment options for each phenotype.4 Exercise testing has a key role in the diagnosis and prognostic assessment of HFpEF.1,5,6 In a study by Alogna et al.,7 398 patients with HFpEF undergoing comprehensive echocardiography and invasive cardiopulmonary exercise testing were categorized low versus preserved biventricular cardiac power output (BCPO) reserve (65%) having a higher risk of events.12–14 Among 11 573 patients hospitalized for HF and enrolled in the nationwide Japanese registry, 16.8% were classified as HFsnEF, 28.3% as HF with normal ejection fraction (HFnEF), 17.5% as HF with mildly reduced ejection fraction (HFmrEF) and 37.4% as HF with reduced ejection fraction (HFrEF). Patients with HFsnEF were older, more likely to be women, had lower natriuretic peptide values, and had smaller left ventricles than those with HFnEF. Patients with HFsnEF, compared to those with HFnEF, had a similar risk of the .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. primary composite endpoint of cardiovascular (CV) death or HF readmission but with a lower adjusted hazard ratio (HR) for HF readmission.15
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.